# A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

Study · id `cardio:ct-nct07192952` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07192952](<https://clinicaltrials.gov/study/NCT07192952>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07192952

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 117 participants.

## Technical summary

Registry record NCT07192952. Allocation not applicable; no masking; primary purpose treatment. Start 2026-06-01 (actual); primary completion 2030-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 117 participants (planned count; ClinicalTrials.gov record NCT07192952, source copy `cardio:ctgov-nct07192952-2026-10-27`, retrieved 2026-10-31)
- Started: 2026-06-01 (actual) (ClinicalTrials.gov record NCT07192952, source copy `cardio:ctgov-nct07192952-2026-10-27`, retrieved 2026-10-31)
- Primary completion: 2030-12-30 (anticipated) (ClinicalTrials.gov record NCT07192952, source copy `cardio:ctgov-nct07192952-2026-10-27`, retrieved 2026-10-31)
- Completion: 2030-12-30 (anticipated) (ClinicalTrials.gov record NCT07192952, source copy `cardio:ctgov-nct07192952-2026-10-27`, retrieved 2026-10-31)
- Countries: United States; Argentina; Austria; Belgium; Brazil; Bulgaria; Canada; Czechia; Finland; Germany; Greece; Hungary; Israel; Italy; Mexico; Poland; Portugal; South Korea; Spain; Sweden; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT07192952, source copy `cardio:ctgov-nct07192952-2026-10-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07192952-2026-10-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
- Acronym: FIORELLO
- Condition: Left Ventricular Systolic Dysfunction
- Condition: Heart Failure (Pediatric)
- Intervention (Drug): Finerenone (Kerendia, BAY94-8862)
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Finerenone (`cardio:finerenone`)
- Registry intervention is a member of this class by a sourced record link: Mineralocorticoid receptor antagonists (drug class) (`cardio:mineralocorticoid-receptor-antagonists`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: 1d06945bf64dbc2084bdb636a3d65ffd517ff304273029c0ad831cd214d414ee
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
